Physician profile
Michael Schmidt
NPI 1710951348
$2,819.37
in general payments reported to CMS, 2019-2025
21 companies · $524 in 2025
The $524 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $83.23 · 2021: $433 · 2022: $486 · 2023: $438 · 2024: $396 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,335.59 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.06 | 2019-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $216.96 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $169.01 | 2019-2021 | |
| Madrigal Pharmaceuticals | $106.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $100.62 | 2019-2025 | Entyvio |
| Pfizer INC. | $97.66 | 2019-2025 | |
| Lilly USA, LLC | $55.44 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $52.10 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $49.03 | 2021 | |
| Celgene Corporation | $43.28 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $37.30 | 2025 | Zenpep |
| Ardelyx, INC. | $32.43 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $30.65 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $21.66 | 2024-2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $20.34 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.71 | 2023 | Dupixent |
| Organon LLC | $16.92 | 2023 | Renflexis |
| Mallinckrodt Hospital Products INC. | $14.78 | 2021 | |
| Boston Scientific Corporation | $14.77 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.